Until a year ago, Pakistan’s pharmaceutical sector was lamenting low profit margins and medicine shortages. But in the first quarter of FY26, the sector recorded its highest-ever after-tax profit of PKR 10.4 billion.

Nukta talks to Asad Ali, senior analyst at Topline Securities, to understand how it happened and what led to the turnaround of the sector’s fortunes.